Affordable GLP-1 Weight Loss Injections in Philadelphia
W8MD Weight Loss, Sleep & MedSpa offers physician-supervised semaglutide and tirzepatide programs, brand-name Wegovy and Zepbound evaluation, oral GLP-1 pills, traditional prescription weight loss medications, nutrition, sleep-apnea care and long-term maintenance at its Northeast Philadelphia office.
- Semaglutide from $29.99+ weekly with an eligible insured visit
- Tirzepatide from $45.00+ weekly with an eligible insured visit
- Affordable self-pay GLP-1 programs
- Wegovy, Zepbound and oral medication evaluation
- Traditional diet pills and nutrition options
- More than 20 years of clinical experience
Affordable GLP-1 Treatment With Medical Guidance
Many patients search only for the lowest weekly medication price. Cost matters, but safe and effective treatment also requires selecting the right medication, checking contraindications, increasing the dose appropriately, managing side effects and planning for long-term maintenance.
W8MD combines affordability with physician-supervised obesity medicine. The medical team reviews the patient’s health history, current medications, previous weight-loss attempts, insurance, personal preference and budget before recommending a plan.
- Medical history and medication-interaction review
- Blood pressure, weight-related risk and sleep assessment
- Choice of injection, daily tablet or traditional medication
- Insurance and prior-authorization support when coverage exists
- Side-effect prevention and dose monitoring
- Nutrition, protein and hydration guidance
- Ongoing follow-up for plateaus and weight maintenance
GLP-1 Weight Loss Injections and Pills Available for Evaluation
W8MD physicians can help eligible Philadelphia-area patients compare weekly GLP-1 injections, dual GIP/GLP-1 treatment and newer oral GLP-1 medications.
Wegovy and Semaglutide
Wegovy is the FDA-approved semaglutide brand for chronic weight management. Semaglutide can reduce hunger, increase fullness and support meaningful weight reduction when combined with nutrition and physical activity.
- Once-weekly injection
- Gradual dose escalation
- Standard-dose and newer higher-dose adult Wegovy options
- Selected additional cardiovascular and liver indications
Zepbound and Tirzepatide
Zepbound is the FDA-approved tirzepatide brand for chronic weight management. Tirzepatide acts at both GIP and GLP-1 receptors.
- Once-weekly injection
- Individual dose escalation and tolerance monitoring
- Also approved for selected adults with obesity-related OSA
- Prior authorization commonly required for brand coverage
Wegovy Tablets
Wegovy tablets contain semaglutide and provide a daily oral alternative for eligible adults. They require specific fasting, water and medication-timing instructions.
- Daily tablet rather than a weekly injection
- Gradual dose escalation
- Empty-stomach administration requirements
- Not the same product or indication as diabetes-dose Rybelsus
Foundayo — Orforglipron
Foundayo is a once-daily, nonpeptide oral GLP-1 receptor agonist approved in 2026 for eligible adults with obesity or overweight plus a qualifying weight-related condition.
- Daily oral treatment
- Can be taken with or without food
- Important drug-interaction and contraceptive considerations
- Availability and insurance coverage may vary
Saxenda — Liraglutide
Saxenda remains an FDA-approved daily injectable option. It may be considered when a shorter-acting GLP-1, daily dosing or a specific insurance formulary makes it a reasonable choice.
Retatrutide, CagriSema and Emerging Treatments
Retatrutide, CagriSema, survodutide, MariTide, VK2735, eloralintide and other next-generation treatments remain investigational for routine obesity care as of July 2026. W8MD can help patients understand new research without presenting unapproved products as available FDA-approved prescriptions.
Compare current and emerging weight loss medicationsAdditional Medical Weight Loss Options at W8MD Philadelphia
A lower-cost traditional medication or nutrition-based program may be more appropriate for some patients, especially when a GLP-1 is not covered, tolerated, available or medically suitable.
Phentermine and Adipex
A short-term stimulant appetite suppressant for selected patients after review of blood pressure, cardiovascular history, insomnia, anxiety, glaucoma, thyroid disease, pregnancy and drug interactions.
Compare prescription weight loss pills →Phentermine and Topiramate
Qsymia is a daily long-term medication that combines phentermine with extended-release topiramate. Pregnancy prevention and monitoring are especially important.
Naltrexone and Bupropion
Contrave may help selected patients with appetite and cravings. It is not appropriate with opioid use and requires seizure, psychiatric, blood-pressure and drug-interaction review.
Diethylpropion and Phendimetrazine
These older appetite suppressants may be considered for selected patients when medically appropriate. They carry stimulant and controlled-substance precautions.
Xenical and Alli
Orlistat reduces absorption of dietary fat. It does not suppress appetite but can cause gastrointestinal effects and may require attention to fat-soluble vitamins and medication interactions.
Low-Calorie Diets and Meal Replacements
W8MD may use lower-carbohydrate, low-glycemic, low-calorie or medically supervised very-low-calorie plans, with optional protein shakes and meal replacements when appropriate.
Explore W8MD nutrition options →Insurance-Supported Visits and Self-Pay Choices
W8MD accepts many insurance plans for qualifying medical visits and offers self-pay options for patients without accepted coverage. Medication coverage is separate from visit coverage.
Semaglutide-Based Programs
$29.99+Per week at a starting dose for certain eligible patients using insurance for the qualifying medical visit.
Published self-pay programs begin at $59.99+ per week.
Tirzepatide-Based Programs
$45.00+Per week at a starting dose for certain eligible patients using insurance for the qualifying medical visit.
Published self-pay programs begin at $69.99+ per week.
Starting prices apply only to qualifying programs and starting doses and may refer to compounded prescription medication when legally available and clinically appropriate. Compounded drugs are not FDA-approved and are not the same as Wegovy or Zepbound. Total cost varies by dose, medication source, pharmacy, shipping, laboratory needs, visit coverage, copay, deductible, coinsurance and other program charges. Brand-name medication pricing is separate and often depends on pharmacy benefits and prior authorization. Prices and availability may change.
How W8MD Helps You Choose the Right Treatment
The least expensive treatment is not a good value if it is unsafe, unavailable, poorly tolerated or impossible to continue. Likewise, the newest medication is not automatically the best medication for every patient.
- Medical history: cardiovascular disease, blood pressure, diabetes, gallbladder disease, pancreatitis, kidney or liver problems, thyroid-cancer history, seizures, glaucoma and other relevant conditions.
- Current medications: diabetes drugs, insulin, opioids, antidepressants, stimulants, seizure medicines, oral contraceptives and drugs affected by delayed gastric emptying.
- Personal preference: weekly injection, daily tablet, stimulant versus nonstimulant treatment and willingness to follow dose-escalation instructions.
- Insurance: formulary, prior authorization, step therapy, copay, deductible and pharmacy benefit.
- Total cost: dose-related medication price, visit, laboratory, shipping and long-term affordability.
- Maintenance: whether the plan remains realistic after the initial weight-loss phase.
Sleep Apnea Care Can Support Weight-Loss Success
Untreated obstructive sleep apnea may contribute to fatigue, impaired concentration, blood-pressure risk and difficulty maintaining nutrition and physical-activity routines. W8MD’s sleep-medicine services distinguish it from many medication-only weight-loss programs.
- Screening for loud snoring and witnessed breathing pauses
- Evaluation of daytime sleepiness and morning headaches
- Convenient home sleep studies for appropriate patients
- Professional interpretation and treatment recommendations
- CPAP, APAP or BPAP support when indicated
- Zepbound evaluation for eligible adults with obesity-related OSA
Weight loss may improve obstructive sleep apnea, but patients should not stop PAP therapy or another prescribed treatment without medical guidance.
Weight Loss Results and Testimonials
W8MD has published patient stories involving substantial weight loss, improved confidence, accountability and long-term maintenance. Testimonials describe individual experiences and do not guarantee a similar result.
“Fantastic program. Truly a life changer.” D.M. reported losing 87 pounds in ten months and later reaching approximately 100 pounds lost with long-term maintenance.D.M. — Published W8MD patient story
A W8MD patient reported losing approximately 150 pounds while emphasizing medical guidance, accountability and ongoing encouragement from the physician and staff.Dawn V. — Published W8MD patient story
A parent reported losing 25 pounds while her daughter lost 58 pounds after participating in the W8MD program together.Published W8MD family success story
How the W8MD Philadelphia Program Works
Request an Appointment
Call the Philadelphia office or submit an online appointment request.
Complete Medical Evaluation
Review health history, weight pattern, current medications, contraindications and prior treatment.
Compare Treatment Choices
Discuss GLP-1 injections, oral medications, traditional pills, nutrition, insurance and cost.
Begin a Personalized Plan
Start the selected medication and nutrition plan when clinically appropriate.
Monitor Response and Safety
Follow appetite, side effects, weight, blood pressure, adherence and medication tolerance.
Plan for Maintenance
Address plateaus, goal-weight transition, medication reassessment and prevention of weight regain.
Serving Philadelphia, Bucks County, Montgomery County and South Jersey
W8MD’s Northeast Philadelphia office is convenient for patients from the city and the surrounding Delaware Valley.
Northeast Philadelphia
Bustleton, Somerton, Rhawnhurst, Fox Chase, Torresdale and nearby Philadelphia neighborhoods.
Bucks County
Bensalem, Feasterville-Trevose, Southampton, Langhorne and nearby communities.
Montgomery County
Huntingdon Valley, Abington, Willow Grove, Jenkintown and surrounding areas.
South Jersey and Delaware
Cherry Hill, Marlton, Voorhees, Camden County and Delaware-area patients who find Philadelphia convenient.
W8MD Weight Loss, Sleep & MedSpa — Philadelphia
1718 Welsh Road2nd Floor, Suite C
Philadelphia, PA 19115 215-676-2334
Learn More About Philadelphia Medical Weight Loss
Affordable GLP-1 Weight Loss Philadelphia FAQ
How much does semaglutide cost at W8MD Philadelphia?
Published starting-dose pricing begins at $29.99 per week for certain eligible patients using insurance for the qualifying medical visit. Published self-pay semaglutide-based programs begin at $59.99 per week and up. Dose, pharmacy, visit coverage and other charges affect total cost.
How much does tirzepatide cost at W8MD Philadelphia?
Published starting-dose pricing begins at $45 per week for certain eligible patients using insurance for the qualifying medical visit. Published self-pay tirzepatide-based programs begin at $69.99 per week and up. Brand-name Zepbound has separate pharmacy pricing and insurance requirements.
Are compounded GLP-1 medications the same as Wegovy or Zepbound?
No. Wegovy and Zepbound are FDA-approved brand-name products. Compounded semaglutide and tirzepatide are not FDA-approved and are not identical to those brands. Legal availability, clinical need, pharmacy licensing and product labeling should be reviewed.
Does W8MD offer Wegovy and Zepbound prior authorization?
W8MD may help eligible patients submit documentation when their insurance plan includes weight-loss medication coverage. The insurer determines approval, formulary requirements and out-of-pocket cost.
Does W8MD offer oral GLP-1 pills?
Eligible adults may ask about FDA-approved Wegovy tablets or Foundayo when medically appropriate and available. Dosing instructions, drug interactions, insurance coverage and costs differ between the two medicines.
Does W8MD prescribe phentermine and other diet pills?
Selected patients may be evaluated for phentermine, Qsymia, Contrave, diethylpropion, phendimetrazine, orlistat, topiramate or another appropriate option. Medical history, blood pressure, pregnancy, drug interactions and contraindications must be reviewed. A consultation does not guarantee a prescription.
Who may qualify for an FDA-approved GLP-1 weight loss medication?
Eligibility depends on the medication. Chronic weight-management products are generally intended for adults with obesity or adults with overweight plus a qualifying weight-related condition. Individual contraindications, pregnancy status and medical history must also be considered.
Can W8MD help patients keep weight off?
W8MD provides ongoing follow-up, medication reassessment, nutrition, plateau management, sleep care and strategies to reduce weight regain. No program can guarantee permanent weight loss, and continued treatment may be needed for a chronic condition.
Does W8MD accept insurance in Philadelphia?
W8MD accepts many insurance plans for qualifying medical visits, but participation varies by provider and plan. Medication coverage is separate from visit coverage. Copays, deductibles, coinsurance, formularies and prior authorization may apply.
Are telehealth appointments available in Pennsylvania?
Telehealth may be available when clinically appropriate and permitted by the patient’s physical location, clinician licensure, medical needs and applicable prescribing rules. Some treatments may require an in-person examination.
FDA Resources
Start an Affordable Physician-Supervised GLP-1 Program in Philadelphia
Meet with W8MD to compare semaglutide, tirzepatide, Wegovy, Zepbound, oral GLP-1 pills, traditional prescription diet medications, nutrition, sleep-apnea evaluation, insurance options and affordable self-pay choices.